These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23905772)

  • 1. Sweet-like syndrome induced by bortezomib.
    Kolb-Mäurer A; Kneitz H; Goebeler M
    J Dtsch Dermatol Ges; 2013 Dec; 11(12):1200-2. PubMed ID: 23905772
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib-induced histiocytoid Sweet syndrome.
    Murase JE; Wu JJ; Theate I; Cole GW; Barr RJ; Dyson SW
    J Am Acad Dermatol; 2009 Mar; 60(3):496-7. PubMed ID: 19231647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma.
    Kim JS; Roh HS; Lee JW; Lee MW; Yu HJ
    Int J Dermatol; 2012 Dec; 51(12):1491-3. PubMed ID: 22998496
    [No Abstract]   [Full Text] [Related]  

  • 5. Images in clinical Medicine. Bortezomib-induced skin lesions.
    Agterof MJ; Biesma DH
    N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bortezomib-induced acute neutrophilic dermatosis].
    Tanguy-Schmidt A; Avenel-Audran M; Croué A; Lissandre S; Dib M; Zidane-Marinnes M; Moles MP; Hunault-Berger M
    Ann Dermatol Venereol; 2009 May; 136(5):443-6. PubMed ID: 19442803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sweet-like lesions induced by bortezomib: a review of the literature and a report of 2 cases.
    Truchuelo M; Bagazgoitia L; Alcántara J; Velasco D; Carrillo R
    Actas Dermosifiliogr; 2012 Nov; 103(9):829-31. PubMed ID: 22652505
    [No Abstract]   [Full Text] [Related]  

  • 8. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
    Obeid KM; Ferrara R; Sharma M
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
    Dehesa L; Bastida J; Limeres-González M; Campos-Adsuar C; Gómez-Duaso J
    Clin Exp Dermatol; 2009 Dec; 34(8):e1031-2. PubMed ID: 20055832
    [No Abstract]   [Full Text] [Related]  

  • 11. Skin lesions induced by bortezomib.
    Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
    Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
    Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 14. Bortezomib-induced skin lesion.
    Ozcan MA; Alacacioglu I; Piskin O; Lebe B; Turgut N; Ceneli S; Demirkan F; Ozsan GH; Undar B
    Acta Haematol; 2006; 116(3):226-7. PubMed ID: 17016047
    [No Abstract]   [Full Text] [Related]  

  • 15. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-associated rash: a new recognizable and avoidable side-effect.
    Villarrubia B; Betlloch I; Mataix J; Lucas A; Botella C
    Br J Dermatol; 2007 Apr; 156(4):784-5. PubMed ID: 17286633
    [No Abstract]   [Full Text] [Related]  

  • 17. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
    Wang HH; Tsui J; Wang XY; Liu SS; Li J
    Leuk Lymphoma; 2014 Jun; 55(6):1404-5. PubMed ID: 23927397
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 20. Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma.
    Paiva CM; Kurtis B; Mekki M; Newman MA; Singhal S; Lacouture ME
    Ann Oncol; 2007 Oct; 18(10):1744-5. PubMed ID: 17890215
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.